A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients
- Conditions
- Relapsed/Refractory Multiple Myeloma
- Interventions
- First Posted Date
- 2024-07-19
- Last Posted Date
- 2024-07-23
- Lead Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Target Recruit Count
- 360
- Registration Number
- NCT06508983
- Locations
- 🇨🇳
Guangzhou First People's Hospital, Guangzhou, Guangdong, China
🇨🇳Beijing Chaoyang Hospital of Capital Medical University, Beijing, Beijing, China
🇨🇳First Affiliated Hospital of Henan University of Science and Technology, Luoyang, Henan, China
SG2918 For Advanced Malignant Tumors
- First Posted Date
- 2023-12-12
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Target Recruit Count
- 117
- Registration Number
- NCT06167486
- Locations
- 🇨🇳
Shanghai first maternity and infant hospital, Shanghai, Shanghai, China
🇨🇳Chongqing University Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Shanxi Provincial Cancer Hospital, Taiyuan, Shanxi, China
SG301-SC Injection Safety Study in Subjects With Systemic Lupus Erythematosus
- Conditions
- Systemic Lupus Erythematosus (SLE)
- Interventions
- Drug: SG301 SC InjectionDrug: SG301 SC Placebo
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT06144710
- Locations
- 🇨🇳
Pingxiang People's Hospital, Pingxiang, Jiangxi, China
🇨🇳Huashan Hospital affiliated to Fudan University, Shanghai, Shanghai, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
An Open-label Study of SG1827 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-10-10
- Last Posted Date
- 2025-03-12
- Lead Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Target Recruit Count
- 122
- Registration Number
- NCT06076291
- Locations
- 🇨🇳
The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, China
🇨🇳Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳The Affiliated Hospital of USTC, Hefei, Anhui, China
SG1906 for CLDN18.2-Positive Solid Tumors
- Conditions
- Locally Advanced Unresectable or Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2023-05-12
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT05857332
- Locations
- 🇨🇳
Liaoning Cancer Hospital, Shenyang, Liaoning, China
🇨🇳The First Hospital of China Medical University, Shenyang, Liaoning, China
🇨🇳The First Affiliated Hospital Of Xiamen University, Xiamen, Fujian, China
SG2501 Safety Study in Subjects with Relapsed or Refractory Hematological Malignancies and Lymphoma.
- First Posted Date
- 2022-03-24
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Target Recruit Count
- 2
- Registration Number
- NCT05293912
- Locations
- 🇺🇸
Northside Hospital, Atlanta, Georgia, United States
🇺🇸Duke University, Durham, North Carolina, United States
🇺🇸Novant Health Cancer Institute Hematology - Forsyth, Winston-Salem, North Carolina, United States
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
- Conditions
- Relapsed or Refractory Multiple MyelomaHematological Malignancy
- Interventions
- First Posted Date
- 2020-12-24
- Last Posted Date
- 2025-03-13
- Lead Sponsor
- Hangzhou Sumgen Biotech Co., Ltd.
- Target Recruit Count
- 61
- Registration Number
- NCT04684108
- Locations
- 🇨🇳
Shenzhen Second People's Hospital, Shenzhen, Guangzhou, China
🇨🇳The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China
🇨🇳Beijing Jishuitan Hostipal, Beijing, Beijing, China